<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03022851</url>
  </required_header>
  <id_info>
    <org_study_id>Occ2016_04</org_study_id>
    <secondary_id>CIV-16-07-016324</secondary_id>
    <nct_id>NCT03022851</nct_id>
  </id_info>
  <brief_title>The Prophet Trial - Pilot Study to Assess Safety and Efficacy of a Novel Atrial Flow Regulator (AFR) in Patients With Pulmonary Hypertension</brief_title>
  <official_title>Prospective, Non-randomized, Pilot Study to Assess Safety and Efficacy of a Novel Atrial Flow Regulator (AFR) in Patients With Pulmonary Hypertension</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Occlutech International AB</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Occlutech International AB</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to investigate safety and efficacy of Occlutech® AFR device in patients with
      severe pulmonary hypertension (PH).
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 19, 2017</start_date>
  <completion_date type="Anticipated">July 2019</completion_date>
  <primary_completion_date type="Anticipated">July 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Absence of Serious Adverse Device Effects (SADES) within 3 month following implantation, including deaths, systemic embolism or device embolizations.</measure>
    <time_frame>0-3 month</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rate of all Serious Adverse Events (SAE) and (Serious) Adverse Device Effects (S)ADEs between 3-12 month post implantation</measure>
    <time_frame>3-12 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evidence of a secure placement of the device and of right-to-left shunt through the AFR device immediately after implantation and 3 month and 12 month after procedure.</measure>
    <time_frame>0-12 month</time_frame>
    <description>The secondary efficacy endpoint will be determined via assessment by color-doppler echocardiography and angiography/fluoroscopy and requires both of:
Device placed in situ [as assessed by the investigator] Evidence of RIGHT TO LEFT shunt through the AFR device [as assessed by the investigator]</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improvement in number of syncopal events due to pulmonary hypertension in the 3 month, 6 months and 12 month after implantation</measure>
    <time_frame>0-12 month</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Pulmonary Hypertension</condition>
  <arm_group>
    <arm_group_label>Occlutech AFR Device</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients who will get the AFR Device implantation</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Occlutech AFR Device</intervention_name>
    <description>Catheter-guided transeptal placement of an AFR device following balloon atrial septostomy (BAS) -procedure.</description>
    <arm_group_label>Occlutech AFR Device</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age is ≥ 18

          -  Patient consents to participation

          -  Patient has had a successful ballon atrial septostomy (BAS)- procedure and is in a
             stable hemodynamic state

          -  Conventional treatment options for the patient are exhausted according to ESC-
             (European Society of Cardiology) and AHA (American Heart Association) -guidelines.

          -  Syncope due to acute Pulmonary Hypertension episodes

          -  Other causes of syncope must have been actively excluded

          -  Syncope or pre-syncope &gt;2 last 3 months

          -  PH (Pulmonary artery pressure (PAP) &gt; 25 mmHg, or pulmonary vascular resistance of &gt; 3
             Wood Units)

          -  Right heart failure, chronic and clinically severe

          -  Severe pulmonary hypertension as evident by echocardiography or catheterisation

        Exclusion Criteria:

          -  Local or generalized sepsis or other acute infection(s)

          -  Thrombophilic coagulation disorder

          -  Allergy to nickel and/or titanium and/or nickel/titanium-based materials

          -  Allergy to anti-platelet, -coagulant, or -thrombotic therapy

          -  Intolerance to contrast agents

          -  Participation in other medical trials shorter than 30 days before the intended AFR
             implantation procedure

          -  Pregnancy

          -  Any intracardiac intervention within the last 30 days

          -  Occluded inferior vena cava access

          -  Previous ASD/PFO closure device in place

          -  Intracardiac thrombus
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Thomas Schöndorf</last_name>
    <phone>+49(0)3641 67 51 20</phone>
    <email>clinicaltrials@occlutech.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Klinikum der Universität München</name>
      <address>
        <city>Munich</city>
        <state>Bavaria</state>
        <zip>81377</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nikolaus Haas, Prof.</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>August 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 10, 2017</study_first_submitted>
  <study_first_submitted_qc>January 12, 2017</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 18, 2017</study_first_posted>
  <last_update_submitted>August 14, 2017</last_update_submitted>
  <last_update_submitted_qc>August 14, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 17, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Hypertension, Pulmonary</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

